LncRNA SNHG6 Upregulates KPNA5 to Overcome Gemcitabine Resistance in Pancreatic Cancer via Sponging miR-944

Gemcitabine (GEM) is the gold-standard therapeutic regimen for patients with pancreatic cancer (PC); however, patients may receive limited benefits due to the drug resistance of GEM. LncRNA SNHG6 is reported to play key roles in drug resistance, but its role and molecular mechanism in PC remain inco...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Ge, Li, Xin, Wu, Hui, Huang, Ling-li, Lin, Yu-xin, Huo, Zhi, Xiang, Zhong-yuan, Zhou, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961296/
https://www.ncbi.nlm.nih.gov/pubmed/37259332
http://dx.doi.org/10.3390/ph16020184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961296/
https://www.ncbi.nlm.nih.gov/pubmed/37259332
http://dx.doi.org/10.3390/ph16020184

Ejemplares similares